TY - JOUR
T1 - Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma
T2 - A prospective, nationwide, multicenter study in Japan
AU - Sugizaki, Katsuya
AU - Tari, Akira
AU - Kitadai, Yasuhiko
AU - Oda, Ichiro
AU - Nakamura, Shotaro
AU - Yoshino, Tadashi
AU - Sugiyama, Toshiro
N1 - Funding Information:
We wish to thank all the staff at the following 34 Japanese medical centers who cooperated with this study and provided valuable data: Tohoku University Hospital (Miyagi), Aichi Cancer Center Hospital (Aichi), University of Toyama (Toyama), Matsue Red Cross Hospital (Shimane), Matsuyama Red Cross Hospital (Ehime), Oita University (Oita), Fukuoka University (Fukuoka), Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (Hiroshima), Hiroshima University Hospital (Hiroshima), Hamamatsu University School of Medicine (Shizuoka), Nagasaki University Hospital (Nagasaki), Saga Medical School (Saga), Kyushu University Hospital (Fukuoka), Niigata Cancer Center Hospital (Niigata), Tsuyama Chuo Hospital (Okayama), Nara City Hospital (Nara), University Hospital Kyoto Prefectural University of Medicine (Kyoto), Hiroshima City Asa Citizens Hospital (Hiroshima), Kindai University (Osaka), Kansai Medical University (Osaka), Kawasaki Medical School (Okayama), Nagoya University Hospital (Aichi), Nagoya City University Hospital (Aichi), Osaka City University (Osaka), Okayama University Hospital (Okayama), National Cancer Center Hospital (Tokyo), National Cancer Center Hospital East (Chiba), Nagano Municipal Hospital (Nagano), Arita GI Hospital (Oita), Masuyama Gastrointestinal Clinic (Tochigi), Toranomon Hospital (Tokyo), Toshiba General Hospital (Tokyo), Hospital of the University of Occupational and Environmental Health (Fukuoka), GI Endoscopy and IBD Center, Aoyama Clinic (Hyogo). We also wish to thank Seiichiro Hojo (Eisai Co., Ltd., Tokyo, Japan) and Saori Katata (EPS Corporation, Tokyo, Japan) for their advice on statistical analysis. This study was funded in full by Eisai Co., Ltd.
Funding Information:
Katsuya Sugizaki is an employee of Eisai Co., Ltd. Katsuya Sugizaki owns stocks and shares in Eisai Co., Ltd. Akira Tari has received research funding from Eisai Co., Ltd. and EA Pharma Co., Ltd. Toshiro Sugiyama has received research funding from Eisai Co., Ltd., EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., and
Publisher Copyright:
© 2018 The Authors. Helicobacter Published by John Wiley & Sons Ltd
PY - 2018/4
Y1 - 2018/4
N2 - Background: Helicobacter pylori eradication therapy was approved in Japan for the first-line, standard treatment of H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small-scale single-center studies have been reported, a prospective, large-scale, nationwide, multicenter study has not been reported from Japan. Materials and Methods: We conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole-based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice-based clinical trial. A total of 108 H. pylori-positive patients with stage I/II1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission (CR) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival (OS). Results: CR of lymphoma was achieved in 84 of 97 patients (86.6%), during the period 2.0-44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1%) for 0.4-53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31%). During follow-up, OS rate was 96.9% (94/97) and the causes of 3 deaths were not related to lymphoma. Conclusions: Rabeprazole-based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice-based, multicenter study.
AB - Background: Helicobacter pylori eradication therapy was approved in Japan for the first-line, standard treatment of H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small-scale single-center studies have been reported, a prospective, large-scale, nationwide, multicenter study has not been reported from Japan. Materials and Methods: We conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole-based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice-based clinical trial. A total of 108 H. pylori-positive patients with stage I/II1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission (CR) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival (OS). Results: CR of lymphoma was achieved in 84 of 97 patients (86.6%), during the period 2.0-44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1%) for 0.4-53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31%). During follow-up, OS rate was 96.9% (94/97) and the causes of 3 deaths were not related to lymphoma. Conclusions: Rabeprazole-based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice-based, multicenter study.
KW - Helicobacter pylori eradication
KW - gastric MALT lymphoma
KW - prospective nationwide multicenter study
KW - rabeprazole-based triple therapy
UR - http://www.scopus.com/inward/record.url?scp=85043302145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043302145&partnerID=8YFLogxK
U2 - 10.1111/hel.12474
DO - 10.1111/hel.12474
M3 - Article
C2 - 29504247
AN - SCOPUS:85043302145
VL - 23
JO - Helicobacter
JF - Helicobacter
SN - 1083-4389
IS - 2
M1 - e12474
ER -